Beta-adrenoceptor involvement in tremor production: possible defects in essential tremor

Kilfeather, S.; Massarella, A.; Turner, P; Findley, L J

doi:10.1007/978-1-349-06757-2_16

Cited by 2 publications

(1 citation statement)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A local defect is not excluded, however. Essential tremor is readily amenable to treatment with beta-blocking drugs, and beta-adrenoceptors may be involved in its production, at least in part, but lymphocyte beta-adrenoceptor function is not abnormal in patients with essential tremor (Kilfeather et al, 1984). It is possible, therefore, that while some ,B-adrenoceptor and epoprostenol in migraine patients pathological conditions in which beta-blockers are of therapeutic value may be associated with generalized changes in beta-adrenoceptor function, others are not, but are due to changes localized to particular tissues.…”

Section: Discussionmentioning

confidence: 99%

Beta-adrenoceptor and epoprostenol (prostacyclin) responsiveness of lymphocytes in migraine patients

Kilfeather¹,

Massarella²,

Gorgolewska³

et al. 1984

Postgraduate Medical Journal

Self Cite

View full text Add to dashboard Cite

SummaryBeta-adrenoceptor blocking drugs are of prophylactic value in some patients with migraine. Beta-adrenoceptor responsiveness as measured by lymphocyte cAMP responsiveness to isoprenaline has, therefore, been compared in ten untreated classical migraine patients and ten matched non-migraine control subjects. Lymphocyte responsiveness to epoprostenol (prostacyclin, PGI2) was also compared. No difference in response to either agent was found between the two groups. A generalized abnormality of betaadrenoceptor function does not appear to be present in classical migraine, but a defect localized to specific vascular regions cannot be excluded.KEY WORDS: isoprenaline, cyclic AMP. IntroductionThe relationship between cardiovascular, neurological and haematological factors in the pathogenesis of migraine is not understood nor, consequently, is the mode of action of prophylactic migraine treatments. As a preliminary study to examination of beta-adrenoceptor and PGI2 receptor functional status during prophylactic treatment of classical migraine with beta-blockers, we have examined the general responsiveness of these vasodilating receptor systems during attack free periods. Beta-adrenoceptor and PGI2 receptor responsiveness was examined on lymphocytes by measuring isoprenaline and PGI2

show abstract

Section: Discussionmentioning

confidence: 99%

Beta-adrenoceptor and epoprostenol (prostacyclin) responsiveness of lymphocytes in migraine patients

Kilfeather¹,

Massarella²,

Gorgolewska³

et al. 1984

Postgraduate Medical Journal

Self Cite

View full text Add to dashboard Cite

show abstract

Is There a Central Nervous Withdrawal Syndrome Associated with Discontinuing Long-term Treatment with Propranolol?

et al. 1988

View full text Add to dashboard Cite

Thirty healthy volunteers were treated with beta-adrenoceptor blocking doses of long-acting propranolol for at least 28 days before being randomized to continue propranolol treatment, receive identical placebo under double-blind conditions, or discontinue all treatment. No evidence of a central nervous withdrawal syndrome occurred during the next 28 days as assessed by changes in psychomotor tests, rating scales, visual analogue scales, tremor recordings and melatonin excretion. Three subjects in the placebo withdrawal group but none in the propranolol group complained of insomnia for up to 14 days of the withdrawal period.

show abstract

Beta-adrenoceptor involvement in tremor production: possible defects in essential tremor

Cited by 2 publications

References 76 publications

Beta-adrenoceptor and epoprostenol (prostacyclin) responsiveness of lymphocytes in migraine patients

Beta-adrenoceptor and epoprostenol (prostacyclin) responsiveness of lymphocytes in migraine patients

Is There a Central Nervous Withdrawal Syndrome Associated with Discontinuing Long-term Treatment with Propranolol?

Contact Info

Product

Resources

About